Search

Your search keyword '"Masuda, Noriyuki"' showing total 678 results
Start Over Author "Masuda, Noriyuki"
678 results on '"Masuda, Noriyuki"'

152. Diagnostic and Prognostic Significances of MUC5B and TTF-1 Expressions in Resected Non-Small Cell Lung Cancer

Author

Nagashio, Ryo, primary, Ueda, Junpei, additional, Ryuge, Shinichiro, additional, Nakashima, Hiroyasu, additional, Jiang, Shi-Xu, additional, Kobayashi, Makoto, additional, Yanagita, Kengo, additional, Katono, Ken, additional, Satoh, Yukitoshi, additional, Masuda, Noriyuki, additional, Murakumo, Yoshiki, additional, Hachimura, Kazuo, additional, and Sato, Yuichi, additional

Published
2015
Full Text
View/download PDF

156. Long-term disease-free survivor of metastatic large-cell neuroendocrine carcinoma of the lung treated with amrubicin and irinotecan

Author

Masuda, Noriyuki

Subjects
Drug Design, Development and Therapy
Abstract

Shinichiro Ryuge1, Shi-Xu Jiang2, Mayuko Wada1, Ken Katono1, Maiko Iwasaki1, Akira Takakura1, Sakiko Otani1, Yuka Kimura1, Tomoya Fukui1, Masanori Yokoba1, Masaru Kubota1, Masato Katagiri1, Kazusige Hayakawa3, Noriyuki Masuda11Department of Respiratory Medicine, 2Department of Pathology, 3Department of Radiology, Kitasato University School of Medicine, Sagamihara, Kanagawa, JapanAbstract: Large-cell neuroendocrine carcinoma (LCNEC) is a relatively uncommon variant of non-small cell lung cancer. Since the biological characteristics of LCNEC are similar to those of small cell lung cancer, LCNEC is usually treated with chemotherapy regimens used for small cell lung cancer. However, the outcomes are usually dismal. Here, we report a patient with LCNEC (a metastasis to the brain). After whole brain irradiation, he received a combination of amrubicin and irinotecan chemotherapy, and has been relapse-free for two years. This treatment regimen may be beneficial for patients with advanced LCNEC. Keywords: large-cell neuroendocrine carcinoma, chemotherapy, amrubicin, irinotecan, lung cancer

Published
2009

157. Next-generation anthracycline for the management of small cell lung cancer: focus on amrubicin

Author

Masuda, Noriyuki

Subjects
Drug Design, Development and Therapy
Abstract

Michiko Yamamoto, Akira Takakura, Noriyuki MasudaDepartment of Respiratory Medicine, Kitasato University School of Medicine, Kitasato, JapanAbstract: Amrubicin is a totally synthetic anthracycline anticancer agent that acts as a potent topoisomerase II inhibitor. Amrubicin has been approved in Japan for the treatment of lung cancer, and the results from clinical studies of amrubicin as a single agent or as part of combination regimens for lung cancer, particularly for small cell lung cancer, conducted in Japan and overseas have been promising. Amrubicin should be included among new treatment strategies especially for chemoresistant patients. Here, preclinical, pharmacological, and clinical data on the use of amrubicin for the treatment of small cell lung cancer are reviewed.Keywords: amrubicin, anthracycline, small-cell lung cancer, extensive disease

Published
2008

168. Circulating tumor cells as a prognostic factor in patients with small cell lung cancer

Author

IGAWA, SATOSHI, primary, GOHDA, KEIGO, additional, FUKUI, TOMOYA, additional, RYUGE, SHINICHIRO, additional, OTANI, SAKIKO, additional, MASAGO, AKINORI, additional, SATO, JUN, additional, MURAKAMI, KATSUHIRO, additional, MAKI, SACHIYO, additional, KATONO, KEN, additional, TAKAKURA, AKIRA, additional, SASAKI, JIICHIRO, additional, SATOH, YUKITOSHI, additional, and MASUDA, NORIYUKI, additional

Published
2014
Full Text
View/download PDF

169. Acquisition of useful sero-diagnostic autoantibodies using the same patients’sera and tumor tissues

Author

KOBAYASHI, Makoto, primary, NAGASHIO, Ryo, additional, RYUGE, Shinichiro, additional, MURAKAMI, Yurie, additional, YANAGITA, Kengo, additional, NAKASHIMA, Hiroyasu, additional, MATSUMOTO, Toshihide, additional, JIANG, Shi-Xu, additional, SAEGUSA, Makoto, additional, SATOH, Yukitoshi, additional, MASUDA, Noriyuki, additional, and SATO, Yuichi, additional

Published
2014
Full Text
View/download PDF

172. Long-term disease-free survivor of metastatic large-cell neuroendocrine carcinoma of the lung treated with amrubicin and irinotecan

Author

Ryuge,Shinichiro, Jiang,Shi-Xu, Wada,Mayuko, Katono,Ken, Iwasaki,Maiko, Takakura,Akira, Otani,Sakiko, Kimura,Yuka, Fukui,Tomoya, Yokoba,Masanori, Kubota,Masaru, Katagiri,Masato, Hayakawa,Kazusige, Masuda,Noriyuki, Ryuge,Shinichiro, Jiang,Shi-Xu, Wada,Mayuko, Katono,Ken, Iwasaki,Maiko, Takakura,Akira, Otani,Sakiko, Kimura,Yuka, Fukui,Tomoya, Yokoba,Masanori, Kubota,Masaru, Katagiri,Masato, Hayakawa,Kazusige, and Masuda,Noriyuki

Abstract

Shinichiro Ryuge1, Shi-Xu Jiang2, Mayuko Wada1, Ken Katono1, Maiko Iwasaki1, Akira Takakura1, Sakiko Otani1, Yuka Kimura1, Tomoya Fukui1, Masanori Yokoba1, Masaru Kubota1, Masato Katagiri1, Kazusige Hayakawa3, Noriyuki Masuda11Department of Respiratory Medicine, 2Department of Pathology, 3Department of Radiology, Kitasato University School of Medicine, Sagamihara, Kanagawa, JapanAbstract: Large-cell neuroendocrine carcinoma (LCNEC) is a relatively uncommon variant of non-small cell lung cancer. Since the biological characteristics of LCNEC are similar to those of small cell lung cancer, LCNEC is usually treated with chemotherapy regimens used for small cell lung cancer. However, the outcomes are usually dismal. Here, we report a patient with LCNEC (a metastasis to the brain). After whole brain irradiation, he received a combination of amrubicin and irinotecan chemotherapy, and has been relapse-free for two years. This treatment regimen may be beneficial for patients with advanced LCNEC. Keywords: large-cell neuroendocrine carcinoma, chemotherapy, amrubicin, irinotecan, lung cancer

Published
2009

173. Next-generation anthracycline for the management of small cell lung cancer: focus on amrubicin

Author

Yamamoto,Michiko, Takakura,Akira, Masuda,Noriyuki, Yamamoto,Michiko, Takakura,Akira, and Masuda,Noriyuki

Abstract

Michiko Yamamoto, Akira Takakura, Noriyuki MasudaDepartment of Respiratory Medicine, Kitasato University School of Medicine, Kitasato, JapanAbstract: Amrubicin is a totally synthetic anthracycline anticancer agent that acts as a potent topoisomerase II inhibitor. Amrubicin has been approved in Japan for the treatment of lung cancer, and the results from clinical studies of amrubicin as a single agent or as part of combination regimens for lung cancer, particularly for small cell lung cancer, conducted in Japan and overseas have been promising. Amrubicin should be included among new treatment strategies especially for chemoresistant patients. Here, preclinical, pharmacological, and clinical data on the use of amrubicin for the treatment of small cell lung cancer are reviewed.Keywords: amrubicin, anthracycline, small-cell lung cancer, extensive disease

Published
2008

180. Effect of Selective Prostaglandin E2 EP2 Receptor Agonist CP-533,536 on Voiding Efficiency in Rats with Midodrine-Induced Functional Urethral Obstruction.

Author

KURIHARA, Ryoko, IMAZUMI, Katsunori, TAKAMATSU, Hajime, ISHIZU, Kenichiro, YOSHINO, Taiji, and MASUDA, Noriyuki

Subjects
PHYSIOLOGICAL effects of prostaglandins, URETHRA diseases, MIDODRINE, LABORATORY rats, URINATION disorders, DISEASE risk factors, THERAPEUTICS
Abstract

Objectives We investigated the effect of the selective prostaglandin E2 EP2 receptor agonist CP-533,536 on voiding efficiency in rats with midodrine-induced functional urethral obstruction. Methods The effect of CP-533,536 (0.03-0.3 mg/kg, intravenous [i.v.]) on urethral perfusion pressure ( UPP) was investigated in anesthetized rats pre-treated with midodrine (1 mg/kg, i.v.), which forms an active metabolite that acts as an α1-adrenoceptor agonist. The effect of CP-533,536 (0.03-0.3 mg/kg, i.v.) on cystometric parameters was also investigated in anesthetized rats. In addition, the effect of CP-533,536 (0.03-0.3 mg/kg, i.v.) on residual urine volume ( RV) and voiding efficiency ( VE) was investigated in conscious rats treated with midodrine (1 mg/kg, i.v.). Results CP-533,536 dose-dependently decreased UPP elevated by midodrine in anesthetized rats. In contrast, CP-533,536 did not affect maximum voiding pressure, intercontraction interval, or intravesical threshold pressure. In conscious rats, midodrine (1 mg/kg, i.v.) markedly increased RV and reduced VE. CP-533,536 dose-dependently ameliorated increases in RV and decreases in VE induced by midodrine. Conclusions These results suggest that a selective EP2 receptor agonist could ameliorate the elevation of RV and improve the reduction of VE in rats with functional urethral obstruction caused by stimulation of α1-adrenoceptors. The mechanism of action might be not potentiation of bladder contraction but rather preferential relief of urethral constriction. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

181. Study on Physiological Roles of Stimulation of Prostaglandin E2 Receptor Subtype EP2 in Urethral Function in Rats.

Author

KURIHARA, Ryoko, ISHIZU, Kenichiro, TAKAMATSU, Hajime, YOSHINO, Taiji, and MASUDA, Noriyuki

Subjects
PHYSIOLOGICAL effects of prostaglandins, MUSCLE relaxants, CYCLIC adenylic acid, LABORATORY rats, URETHRA diseases, THERAPEUTICS
Abstract

Objectives We investigated the relaxant effect of stimulation of prostaglandin E2 ( PGE2) receptor subtype EP2 as well as the involvement of a cyclic AMP ( cAMP)-dependent pathway related to stimulation of EP2 receptors in urethral function in rats by evaluating effects of PGE2 and selective EP2 receptor agonist CP-533,536. Methods Effects of PGE2 and CP-533,536 on cAMP accumulation were assessed in Chinese hamster ovary ( CHO)- K1 cells expressing rat EP2 or EP4 receptors. Relaxant responses to PGE2 and CP-533,536 (0.01-10 µmol/L) in rat urethral tissue pre-contracted with 10 µmol/L phenylephrine were evaluated, and cAMP levels in isolated rat urethral tissue treated with these compounds were determined as well. The effects of PGE2 and CP-533,536 (0.003-0.3 mg/kg intravenously) on urethral perfusion pressure ( UPP) in anesthetized rats were also evaluated. Results PGE2 concentration-dependently increased the accumulation of cAMP in cells expressing rat EP2 ( EC50 value = 1.3 nmol/L) and EP4 receptors ( EC50 value = 17 nmol/L). While CP-533,536 similarly increased the accumulation of cAMP in cells expressing rat EP2 receptors ( EC50 value = 3.0 nmol/L), no such effects were noted in cells expressing rat EP4 receptors up to 10 µmol/L. Both PGE2 and CP-533,536 produced relaxation and increased cAMP levels in urethral tissues in a concentration-dependent manner. PGE2 and CP-533,536 both dose-dependently decreased UPP in anesthetized rats. Conclusions Taken together, these results suggest that stimulation of EP2 receptors induces relaxation likely via activation of cAMP-dependent mechanisms in rat urethral tissue, leading to a reduction of UPP. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

182. Prognostic factors affecting the risk of thoracic progression in extensive-stage small cell lung cancer.

Author

Tomoya Fukui, Michiko Itabashi, Mikiko Ishihara, Yasuhiro Hiyoshi, Masashi Kasajima, Satoshi Igawa, Jiichiro Sasaki, Noriyuki Masuda, Fukui, Tomoya, Itabashi, Michiko, Ishihara, Mikiko, Hiyoshi, Yasuhiro, Kasajima, Masashi, Igawa, Satoshi, Sasaki, Jiichiro, and Masuda, Noriyuki

Subjects
CANCER treatment, SMALL cell lung cancer, CANCER risk factors, RADIOTHERAPY, CANCER chemotherapy, PROGNOSIS, LUNG cancer treatment, TREATMENT of lung tumors, ANTHROPOMETRY, COMBINED modality therapy, LUNG cancer, LUNG tumors, METASTASIS, TUMOR classification, TREATMENT effectiveness, PROPORTIONAL hazards models, DISEASE progression, CHEST (Anatomy), KAPLAN-Meier estimator
Abstract

Background: The efficacy of combined modality therapy is evaluated for patients with extensive-stage (ES) small cell lung cancer (SCLC). This study evaluated prognostic factors affecting the risk of thoracic progression in ES-SCLC patients likely to undergo thoracic radiotherapy combined chemotherapy.Methods: A retrospective review of ES-SCLC patients who had received systemic chemotherapy at our hospital was performed. Tumor size, metastatic sites, and laboratory data at diagnosis were evaluated as potential prognostic factors. In ES-SCLC patients without pleural dissemination, the rate of thoracic progression after initial chemotherapy was assessed.Results: Eighty-three of 96 consecutive ES-SCLC patients were analyzed. The overall response rate was 55 %, median progression free survival was 5.0 months (mo), and overall survival (OS) was 9.2 mo. Tumor size (19.4 mo for ≤3 cm vs. 8.5 mo for >3 cm, p = 0.017) and the number of metastatic sites (12.9 mo for single sites vs. 7.1 mo for multiple sites, p = 0.015) were prognostic factors, in addition to known prognostic factors such as performance status and the levels of LDH and sodium. Cox proportional hazard model showed that the OS was significantly worse in patients with large (>3 cm) primary tumor size {HR 2.44 [95 % confidential interval (CI) 1.05-5.68], p = 0.038} and multiple metastatic sites [HR 1.81 (95 % CI 1.08-3.04), p = 0.026]. In 51 cases without pleural dissemination, the number of metastatic sites was associated with thoracic progression after initial chemotherapy (65 % for single sites vs. 36 % for multiple sites, p = 0.036).Conclusion: Large tumor size and multiple metastatic sites at diagnosis significantly predicted poor survival in ES-SCLC patients. Based on the high rate of thoracic progression in ES-SCLC patients with single site of distant metastasis, we should consider thoracic radiotherapy combined with chemotherapy for this population. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

189. Printed hybrid systems

Author

Karioja, Pentti, primary, Mäkinen, Jukka-Tapani, additional, Keränen, Kimmo, additional, Aikio, Janne, additional, Alajoki, Teemu, additional, Jaakola, Tuomo, additional, Koponen, Matti, additional, Keränen, Antti, additional, Heikkinen, Mikko, additional, Tuomikoski, Markus, additional, Suhonen, Riikka, additional, Hakalahti, Leena, additional, Kopola, Pälvi, additional, Hast, Jukka, additional, Liedert, Ralf, additional, Hiltunen, Jussi, additional, Masuda, Noriyuki, additional, Kemppainen, Antti, additional, Rönkä, Kari, additional, and Korhonen, Raimo, additional

Published
2012
Full Text
View/download PDF

190. Phase I Results of Vinorelbine With Concurrent Radiotherapy in Elderly Patients With Unresectable, Locally Advanced Non-Small-Cell Lung Cancer: West Japan Thoracic Oncology Group (WJTOG3005-DI)

Author

Harada, Hideyuki, primary, Seto, Takashi, additional, Igawa, Satoshi, additional, Tsuya, Asuka, additional, Wada, Mayuko, additional, Kaira, Kyoichi, additional, Naito, Tateaki, additional, Hayakawa, Kazushige, additional, Nishimura, Tetsuo, additional, Masuda, Noriyuki, additional, and Yamamoto, Nobuyuki, additional

Published
2012
Full Text
View/download PDF

191. CAXII Is a Sero-Diagnostic Marker for Lung Cancer

Author

Kobayashi, Makoto, primary, Matsumoto, Toshihide, additional, Ryuge, Shinichiro, additional, Yanagita, Kengo, additional, Nagashio, Ryo, additional, Kawakami, Yoshitaka, additional, Goshima, Naoki, additional, Jiang, Shi-Xu, additional, Saegusa, Makoto, additional, Iyoda, Akira, additional, Satoh, Yukitoshi, additional, Masuda, Noriyuki, additional, and Sato, Yuichi, additional

Published
2012
Full Text
View/download PDF

195. Rapid deconjugation of SN-38 glucuronide and adsorption of released free SN-38 by intestinal microorganisms in rat

Author

TAKAKURA, AKIRA, primary, KURITA, AKINOBU, additional, ASAHARA, TAKASHI, additional, YOKOBA, MASANORI, additional, YAMAMOTO, MICHIKO, additional, RYUGE, SHINICHIRO, additional, IGAWA, SATOSHI, additional, YASUZAWA, YUKITOSHI, additional, SASAKI, JIICHIRO, additional, KOBAYASHI, HIROSUKE, additional, and MASUDA, NORIYUKI, additional

Published
2011
Full Text
View/download PDF

196. A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy

Author

Aogi, Kenjiro, primary, Sakai, Hiroshi, additional, Yoshizawa, Hirohisa, additional, Masuda, Norikazu, additional, Katakami, Nobuyuki, additional, Yanagita, Yasuhiro, additional, Inoue, Kenichi, additional, Kuranami, Masaru, additional, Mizutani, Mitsuhiro, additional, and Masuda, Noriyuki, additional

Published
2011
Full Text
View/download PDF

198. Phase I and pharmacologic study of BNP7787, a novel chemoprotector in patients with advanced non-small cell lung cancer

Author

Masuda, Noriyuki, primary, Negoro, Shunichi, additional, Hausheer, Frederick, additional, Nakagawa, Kazuhiko, additional, Matsui, Kaoru, additional, Kudoh, Shinzoh, additional, Takeda, Koji, additional, Yamamoto, Nobuyuki, additional, Yoshimura, Naruo, additional, Ohashi, Yasuo, additional, and Fukuoka, Masahiro, additional

Published
2010
Full Text
View/download PDF

199. Abstract 2232: Circulating tumor cells in peripheral venous blood of primary lung cancer patients: detection using adenovirus GFP-labeling

Author

Satoh, Yukitoshi, primary, Matsui, Yoshio, additional, Ogawa, Fumihiro, additional, Amano, Hideki, additional, Hara, Hidenori, additional, Nezu, Kenji, additional, Iyoda, Akira, additional, Yoshimura, Hirokuni, additional, Fukui, Tomoya, additional, Igawa, Satoshi, additional, Katagiri, Makoto, additional, Masuda, Noriyuki, additional, Masago, Akinori, additional, and Tsujino, Yukio, additional

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results